GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Origin Therapeutics Holdings Inc (XCNQ:ORIG) » Definitions » Intrinsic Value: Projected FCF

Origin Therapeutics Holdings (XCNQ:ORIG) Intrinsic Value: Projected FCF : C$0.00 (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-09), Origin Therapeutics Holdings's Intrinsic Value: Projected FCF is C$0.00. The stock price of Origin Therapeutics Holdings is C$0.025. Therefore, Origin Therapeutics Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Origin Therapeutics Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

XCNQ:ORIG's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.575
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Origin Therapeutics Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for Origin Therapeutics Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings Intrinsic Value: Projected FCF Chart

Origin Therapeutics Holdings Annual Data
Trend Sep21 Sep22
Intrinsic Value: Projected FCF
- -

Origin Therapeutics Holdings Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Origin Therapeutics Holdings's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Origin Therapeutics Holdings's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's Price-to-Projected-FCF falls into.



Origin Therapeutics Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Origin Therapeutics Holdings  (XCNQ:ORIG) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Origin Therapeutics Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.025/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Origin Therapeutics Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Origin Therapeutics Holdings (XCNQ:ORIG) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
505 Burrard Street, Suite 1570, Vancouver, BC, CAN, V7X 1M5
Origin Therapeutics Holdings Inc is an investment company focusing on investments in the psychedelic industry.

Origin Therapeutics Holdings (XCNQ:ORIG) Headlines

From GuruFocus

Paul Singer's 6 Largest New Holdings

By Sydnee Gatewood Sydnee Gatewood 11-28-2017

Transocean Ltd. Closes the Acquisition of Ocean Rig UDW Inc.

By Marketwired Marketwired 12-05-2018

Third Avenue Value Fund 3rd Quarter Letter

By Holly LaFon Holly LaFon 11-01-2018

3 Reasons to Buy an Ocean Rig

By Subia Khan Value Investor 04-04-2014

Buy Ocean Rig Before Quarterly Results

By Faisal Humayun Faisal Humayun 02-09-2015

Ocean Rig UDW Inc Joins the Russell 3000® Index

By Marketwired Marketwired 06-26-2018

5 Energy Stocks in Gurus' Portfolios

By Tiziano Frateschi Tiziano Frateschi 06-01-2018